Gaspard du Chaffaut

Gaspard is an associate in Goodwin’s Technology and Life Sciences groups in the firm’s London office. Gaspard advises clients on a broad range of corporate matters. He has particular experience advising on private equity and venture capital investments and exits, mergers and acquisitions, corporate financings and reorganisations, as well as general corporate matters. Gaspard advises clients through every stage of the corporate life cycle.

• ReStabilise on its £2.82 million pre-seed investment round led by Project A
• Tenpoint Therapeutics on securing $235 million through its Series B and a credit facility
• Dark Blue Therapeutics on its up to $840 million acquisition by Amgen